Four climbers went up and down Everest in under a week with the help of xenon gas—a record-breaking ascent that has ignited controversy in the mountaineering world.

A small crew out of the UK summited Everest in days with the help of xenon gas. Here's what xenon gas is, why it's used for climbing, and the risks of using it.

Mount Everest’s Xenon-Gas Controversy Will Last Forever History is repeating itself in the world of controversial sports records.

Climbers using xenon gas reached the summit of Everest in under five days but critics say the shortcut could lead to dangerous overcrowding and undermine the spirit of mountaineering.

The use of xenon gas by a group of British mountaineers before they began an expedition to climb the world's highest mountain in less than five days has raised questions about its effectiveness ...

British climbers recently reached the top of Mount Everest in record time. They inhaled xenon gas before the trip. But was that the decisive factor?

Using xenon gas treatment and the latest technology is making climbing Mount Everest not just faster but also better for the environment, cutting down garbage and waste, a renowned mountain guide ...

Xenon is a colourless, odourless gas with anaesthetic properties that can improve acclimatisation and protect against altitude sickness.

Four British climbers became the first to scale Mount Everest on Wednesday using Xenon gas, which helped them save several weeks that mountaineers need to get used to high altitudes, an official ...

VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) decreased by 17.43 percent on Tuesday to finish at $29.60 apiece following the delayed results of its Phase 3 epilepsy study and a dismal earnings ...

Xenon also announced the start of a Phase 1 study for XEN1120, a follow-on Kv7 channel opener, and expects to file an IND for XEN1701, its lead Nav1.7 candidate, in Q3 2025.